Skip to main content
. 2019 Dec 10;93(24):e2294–e2305. doi: 10.1212/WNL.0000000000008620

Table 3.

Percentage of participants with treatment-emergent adverse events by trial arm and type (>15% in either group)

graphic file with name NEUROLOGY2018963033TT3.jpg